Adoptive cell transfer in the treatment of metastatic melanoma

TY - JOUR

T1 - Adoptive cell transfer in the treatment of metastatic melanoma

AU - Straten, Per thor

AU - Becker, Jürgen C

N1 - Keywords: Adoptive Transfer; Humans; Melanoma; Skin Neoplasms

PY - 2009

Y1 - 2009

N2 - Adoptive cell therapy (ACT) for metastatic cancer is the focus of considerable research effort. Rosenberg's laboratory demonstrated a 50% response rate in stage IV melanoma patients treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) and high-dose IL-2 administered after nonmyeloablative conditioning (Dudley et al., 2002a). Because early attempts to use expanded TILs in melanoma therapy failed to demonstrate better efficacy than high-dose IL-2 (Rosenberg et al., 1994), the efficacy of TILs and nonmyeloablative conditioning in combination implies that patient conditioning is crucial to clinical success. The 2002 data represent a milestone in cellular cancer therapy and a turning point for ACT in cancer treatment.

AB - Adoptive cell therapy (ACT) for metastatic cancer is the focus of considerable research effort. Rosenberg's laboratory demonstrated a 50% response rate in stage IV melanoma patients treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) and high-dose IL-2 administered after nonmyeloablative conditioning (Dudley et al., 2002a). Because early attempts to use expanded TILs in melanoma therapy failed to demonstrate better efficacy than high-dose IL-2 (Rosenberg et al., 1994), the efficacy of TILs and nonmyeloablative conditioning in combination implies that patient conditioning is crucial to clinical success. The 2002 data represent a milestone in cellular cancer therapy and a turning point for ACT in cancer treatment.

U2 - 10.1038/jid.2009.204

DO - 10.1038/jid.2009.204

M3 - Journal article

C2 - 19901944

SN - 0022-202X

VL - 129

SP - 2743

EP - 2745

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 12

ER -